Will a new administration mean a better CBD outlook from FDA? – podcastWill a new administration mean a better CBD outlook from FDA? – podcast
A dietary supplements regulatory veteran weighs in on CBD's shifting fortunes under a Biden administration.
ToddCast Vol. XXIX: Duffy MacKay has lived and breathed Washington, D.C., for a decade as senior vice president of scientific and regulatory affairs for the Council for Responsible Nutrition, a leading trade group serving the dietary supplements industry. Like so many other supplements veterans, he jumped ship and swam to the boisterous shores of hemp CBD land. MacKay sits down with Insider senior editor Todd Runestad to talk about the similarities between the last quarter-century of supplements and the last five of CBD, in particular as it relates to FDA regulation. Tune in as they discuss:
How CBD companies don’t quite get that they are in the supplements business, not the marijuana business. Rules and regulations apply.
Whether potential FDA commissioner in the Biden administration, David Kessler, has “evolved his thinking” from supplements enemy to hemp accepter if not promoter.
Whether Congress can write laws to compel the FDA to stop its slow-dance of hemp CBD regulations.
Read more about:Podcasts
About the Author(s)
You May Also Like